Academic Journal
Co-clinical CT radiomics pipeline to establish candidate imaging biomarkers for colorectal cancer.
| Τίτλος: | Co-clinical CT radiomics pipeline to establish candidate imaging biomarkers for colorectal cancer. |
|---|---|
| Συγγραφείς: | Connor K; Discipline of Physiology, School of Medicine, Trinity College Dublin, Ireland; RCSI Precision Cancer Medicine Group, Department of Physiology and Medical Physics, Royal College of Surgeons in Ireland, Dublin, Ireland; National Pre-clinical Imaging Centre, Dublin, Ireland. Electronic address: connorka@tcd.ie., Prior O; Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Hospital Campus, IIS IR-HUVH, 08035 Barcelona, Spain. Electronic address: oliviaprior@vhio.net., Shiels LP; RCSI Precision Cancer Medicine Group, Department of Physiology and Medical Physics, Royal College of Surgeons in Ireland, Dublin, Ireland; National Pre-clinical Imaging Centre, Dublin, Ireland. Electronic address: liamshiels@rcsi.ie., Connolly C; RCSI Precision Cancer Medicine Group, Department of Physiology and Medical Physics, Royal College of Surgeons in Ireland, Dublin, Ireland; National Pre-clinical Imaging Centre, Dublin, Ireland. Electronic address: columconnolly@rcsi.ie., Miller IS; RCSI Precision Cancer Medicine Group, Department of Physiology and Medical Physics, Royal College of Surgeons in Ireland, Dublin, Ireland; National Pre-clinical Imaging Centre, Dublin, Ireland. Electronic address: iansmiller@gmail.com., Crean R; Department of Surgery, Royal College of Surgeons in Ireland, Dublin, Ireland. Electronic address: rorycrean@rcsi.ie., Murphy S; RCSI Precision Cancer Medicine Group, Department of Physiology and Medical Physics, Royal College of Surgeons in Ireland, Dublin, Ireland; Department of Neurosurgery, Beaumont Hospital, Dublin, Ireland; National Pre-clinical Imaging Centre, Dublin, Ireland. Electronic address: suzannemmurphy@rcsi.ie., McGuinness G; Disipline of Medical Education, School of Medicine, Trinity College Dublin, Ireland., Monreal C; Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Hospital Campus, IIS IR-HUVH, 08035 Barcelona, Spain. Electronic address: camilomonreal@vhio.net., Serna G; Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Hospital Campus, IIS IR-HUVH, 08035 Barcelona, Spain. Electronic address: gserna@vhio.net., Idemudia E; Graduate Entry Medicine, Department of Medicine, Royal College of Surgeons in Ireland, Dublin, Ireland. Electronic address: ehitaidemudia22@rcsi.ie., Eriksen G; Graduate Entry Medicine, Department of Medicine, Royal College of Surgeons in Ireland, Dublin, Ireland. Electronic address: gregoryeriksen22@rcsi.ie., Haworth E; Graduate Entry Medicine, Department of Medicine, Royal College of Surgeons in Ireland, Dublin, Ireland. Electronic address: evinhaworth23@rcsi.ie., Prehn JHM; RCSI Precision Cancer Medicine Group, Department of Physiology and Medical Physics, Royal College of Surgeons in Ireland, Dublin, Ireland; National Pre-clinical Imaging Centre, Dublin, Ireland. Electronic address: jprehn@rcsi.ie., Tabernero J; Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Hospital Campus, IIS IR-HUVH, 08035 Barcelona, Spain. Electronic address: jtabernero@vhio.net., Elez E; Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Hospital Campus, IIS IR-HUVH, 08035 Barcelona, Spain. Electronic address: meelez@vhio.net., O'Farrell AC; RCSI Precision Cancer Medicine Group, Department of Physiology and Medical Physics, Royal College of Surgeons in Ireland, Dublin, Ireland; National Pre-clinical Imaging Centre, Dublin, Ireland. Electronic address: aliceofarrell@rcsi.ie., O'Brien D; Department of Neurosurgery, Beaumont Hospital, Dublin, Ireland. Electronic address: davidobrien1@beaumont.ie., Toledo R; Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Hospital Campus, IIS IR-HUVH, 08035 Barcelona, Spain. Electronic address: rtoledo@vhio.net., Nuciforo P; Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Hospital Campus, IIS IR-HUVH, 08035 Barcelona, Spain. Electronic address: pnuciforo@vhio.net., Butterworth KT; Johnston Cancer Research Centre, Queen's University Belfast, Belfast, UK. Electronic address: k.butterworth@qub.ac.uk., Dienstmann R; Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Hospital Campus, IIS IR-HUVH, 08035 Barcelona, Spain. Electronic address: rdienstmann@vhio.net., Perez-Lopez R; Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Hospital Campus, IIS IR-HUVH, 08035 Barcelona, Spain., Byrne AT; RCSI Precision Cancer Medicine Group, Department of Physiology and Medical Physics, Royal College of Surgeons in Ireland, Dublin, Ireland; National Pre-clinical Imaging Centre, Dublin, Ireland. Electronic address: annettebyrne@rcsi.ie. |
| Πηγή: | European journal of radiology [Eur J Radiol] 2026 Oct; Vol. 203, pp. 113038. Date of Electronic Publication: 2026 Jun 28. |
| Τύπος έκδοσης: | Journal Article |
| Γλώσσα: | English |
| Στοιχεία περιοδικού: | Publisher: Elsevier Science Ireland Ltd Country of Publication: Ireland NLM ID: 8106411 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1872-7727 (Electronic) Linking ISSN: 0720048X NLM ISO Abbreviation: Eur J Radiol Subsets: MEDLINE |
| Imprint Name(s): | Publication: Limerick : Elsevier Science Ireland Ltd Original Publication: Stuttgart ; New York : Thieme, [c1981- |
| Ιατρικοί όροι (MeSH): | Colorectal Neoplasms*/diagnostic imaging , Colorectal Neoplasms*/drug therapy , Tomography, X-Ray Computed*/methods , Liver Neoplasms*/diagnostic imaging , Liver Neoplasms*/secondary , Radiographic Image Interpretation, Computer-Assisted*/methods , Biomarkers, Tumor*, Radiomics ; Humans ; Sensitivity and Specificity ; Animals ; Reproducibility of Results ; Female ; Mice ; Male ; Treatment Outcome |
| Περίληψη: | Here, we establish a co-clinical computed tomography (CT) radiomics pipeline for the identification of candidate imaging biomarkers in RAS-mutant metastatic colorectal cancer (mCRC). Orthotopic KRAS-mutant xenograft models (LOVO-Luc2 (N = 52) and SW480-Luc2 (N = 52)) were treated with standard-of-care regimens (FOLFOX, bevacizumab, or combination) and longitudinally imaged by CT (N = 104 tumour scans, N = 156 liver scans collected over 4 timepoints). Radiomic features derived from primary tumour and liver parenchyma were assessed as biomarkers of treatment sensitivity and early metastatic disease. Pre-treatment CT-radiomics identified baseline radiomic correlates of treatment sensitivity in the LOVO-Luc2 model (0.716), with first-order statistical features (Median, 10percentile) significantly associated with therapy outcome. Texture-based liver radiomic features enabled prediction of metastases earlier than visual CT assessment (AUROC = 0.871). The most predictive features, GLSZM Gray Level Non-Uniformity, GLRLM Run Length Non-Uniformity Normalized, and GLDM Small Dependence Emphasis, were significantly associated with metastatic burden and survival in a clinical CRC cohort (N = 41), indicating species conservation and translational relevance. Collectively, these data demonstrate that preclinical CT radiomics can identify quantitative imaging features associated with treatment sensitivity and early metastatic progression, supporting translational potential. (Copyright © 2026 The Author(s). Published by Elsevier B.V. All rights reserved.) |
| Competing Interests: | Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: J. Tabernero reports personal financial interest in form of scientific consultancy role for Accent Therapeutics, Alentis Therapeutics, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Carina Biotech, Cartography Biosciences, Chugai, Daiichi Sankyo, F. Hoffmann-La Roche, Genentech, Johnson & Johnson/Janssen, Lilly, Marengo Therapeutics, Menarini, Merus, MSD, Novartis, Ono Pharma USA, Peptomyc, Pfizer, Pierre Fabre, QuantroTherapeutics, ScandionOncology, Scorpion Therapeutics, Servier, Sotio Biotech, SynteliosAG, Taiho, Takeda Oncology and Tolremo Therapeutics; and stocks from Alentis Therapeutics, OniriaTherapeutics, 1TRIALSP and Pangaea Oncology. There are no other competing interests to declare. |
| Contributed Indexing: | Keywords: Colorectal cancer; Computed tomography; Liver metastasis; Precision medicine; Radiomics |
| Substance Nomenclature: | 0 (Biomarkers, Tumor) |
| Entry Date(s): | Date Created: 20260701 Date Completed: 20260809 Latest Revision: 20260809 |
| Update Code: | 20260810 |
| DOI: | 10.1016/j.ejrad.2026.113038 |
| PMID: | 42385277 |
| Βάση Δεδομένων: | MEDLINE |
| ISSN: | 1872-7727 |
|---|---|
| DOI: | 10.1016/j.ejrad.2026.113038 |